1.05BMarket Cap
9.59P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of CureVac NV
Currency: USD Updated: 2026-01-05 Key Insights
CureVac NV's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 401 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 4.68.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
CureVac NV Highlights
StrengthsRisks
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-05 Its latest quarterly revenue reached 46.99M, representing a year-over-year decrease of 89.89%, while its net profit experienced a year-over-year decrease of 25.47%.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Key Metrics
Relevant data have not been disclosed by the company yet.
CureVac NV's Company Valuation
Currency: USD Updated: 2026-01-05The current valuation score of CureVac NV is 8.25, ranking 58 out of 401 in the Biotechnology & Medical Research industry. Its current P/E ratio is 9.59, which is 17.81% below the recent high of 11.30 and 237.04% above the recent low of -13.15.
Valuation Dimensions
Industry Ranking 40/401
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-05The current earnings forecast score of CureVac NV is 6.40, ranking 340 out of 401 in the Biotechnology & Medical Research industry. The average price target is 5.46, with a high of 5.50 and a low of 2.00.
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-05The current price momentum score of CureVac NV is 6.97, ranking 120 out of 401 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.31 and the support level at 4.00, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2026-01-05Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Alpine Associates Management Inc.
Qube Research & Technologies Ltd
Bill & Melinda Gates Foundation
AQR Capital Management, LLC
Water Island Capital, LLC
Magnetar Capital Partners LP
BlackRock Institutional Trust Company, N.A.
RBC Dominion Securities, Inc.
Risk Assessment
Currency: USD Updated: 2026-01-05The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CureVac NV is 9.81, ranking 1 out of 401 in the Biotechnology & Medical Research industry. The company's beta value is 1.87. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Beta vs S&P 500 index
1.87
240-Day Maximum Drawdown
+37.44%
240-Day Volatility
+56.29%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Biotechnology & Medical Research
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
